MCF 10A Ecadherin EmGFP
CRL-10317EMT ™
MCF 10A Ecadherin EmGFP was CRISPR-edited to aid in the study of epithelial to mesenchymal transition (EMT) in breast cancer. This cell line can be used in drug development and, assay development.
- Product category
-
Human cells
- Product type
-
Cell model
- Organism
-
Homo sapiens, human
- Morphology
- epithelial
- Tissue
- Breast; Mammary gland
- Disease
-
Fibrocystic Disease
- Applications
-
3D cell cultureDrug developmentHigh-throughput screeningAssay development
- Product format
- Frozen
- Storage conditions
-
Vapor phase of liquid nitrogen
Documentation
ATCC determines the biosafety level of a material based on our risk assessment as guided by the current edition of Biosafety in Microbiological and Biomedical Laboratories (BMBL), U.S. Department of Health and Human Services. It is your responsibility to understand the hazards associated with the material per your organization’s policies and procedures as well as any other applicable regulations as enforced by your local or national agencies.
ATCC highly recommends that appropriate personal protective equipment is always used when handling vials. For cultures that require storage in liquid nitrogen, it is important to note that some vials may leak when submersed in liquid nitrogen and will slowly fill with liquid nitrogen. Upon thawing, the conversion of the liquid nitrogen back to its gas phase may result in the vial exploding or blowing off its cap with dangerous force creating flying debris. Unless necessary, ATCC recommends that these cultures be stored in the vapor phase of liquid nitrogen rather than submersed in liquid nitrogen.
Required Products
These products are vital for the proper use of this item and have been confirmed as effective in supporting functionality. If you use alternative products, the quality and effectiveness of the item may be affected.
Detailed product information
General
- Specific applications
- Epithelial to mesenchymal transition (EMT), anti-EMT drug screening, breast cancer drug screening, E-cadherin expression dynamics.
Characteristics
- Cells per vial
- Approximately 1.0 x 106
- Volume
- 1.0 mL
- Growth properties
- Adherent
- Age
- 36 years
- Ethnicity
- White
- Gender
- Female
- Comments
- Cells undergoing EMT often display downregulation of epithelial markers (such as E-cadherin; ECAD) and upregulation of mesenchymal markers (such as vimentin; VIM). Here, we created an ECAD-EmGFP reporter cell line (ATCC CRL-10317EMT) using the CRISPR/Cas9 gene editing platform and the parental MCF 10A (ATCC CRL-10317). The created CRL-10317EMT cell line harbors a C-terminal green fluorescent protein (EmGFP) tag on the E-cadherin gene. This will enable the tracking of the EMT status of cells in vitro by monitoring GFP expression. The integrity of the ECAD-EmGFP knock-in has been verified at the genomic, mRNA and protein level for sequence and expression. The MCF 10A ECAD-EmGFP reporter cell line provides a convenient and sensitive platform for research on the mechanisms of metastasis in vitro and the development of new antitumor drugs for metastatic breast cancer.
Handling information
- Unpacking and storage instructions
-
- Check all containers for leakage or breakage.
- Remove the frozen cells from the dry ice packaging and immediately place the cells at a temperature below -130°C, preferably in liquid nitrogen vapor, until ready for use.
- Complete medium
-
The base medium for this cell line (MEBM) along with the additives can be obtained from Lonza/Clonetics Corporation as a kit: MEGM, Kit Catalog No. CC-3150. ATCC does not use the GA-1000 (gentamycin-amphotericin B mix) provided with kit. To make the complete growth medium, you will need to add the following components to the kit (sold separately):
- 100 ng/ml cholera toxin
- Temperature
-
37°C
- Atmosphere
-
95% Air, 5% CO2
- Handling procedure
-
To ensure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C. Storage at -70°C will result in loss of viability.
- Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 minutes).
- Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.
- Transfer the vial contents to a centrifuge tube containing 9.0 mL complete culture medium. and spin at approximately 125 x g for 5 to 10 minutes.
- Resuspend cell pellet with the recommended complete medium (see the specific batch information for the culture recommended dilution ratio) and dispense into a 25 cm2 or 75 cm2 culture flask. It is important to avoid excessive alkalinity of the medium during recovery of the cells. It is suggested that, prior to the addition of the vial contents, the culture vessel containing the complete growth medium be placed into the incubator for at least 15 minutes to allow the medium to reach its normal pH (7.0 to 7.6). pH (7.0 to 7.6).
- Incubate the culture at 37°C in a suitable incubator. A 5% CO2 in air atmosphere is recommended if using the medium described on this product sheet.
- Subculturing procedure
-
Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes. Corning® T-75 flasks (catalog #430641) are recommended for subculturing this product.
- Remove medium and rinse monolayer with PBS (ATCC 30-2200) .
- Add 3.0 mL of 0.05% trypsin, 0.53 mM EDTA and incubate 37°C for 15 minutes. br />
- To neutralize trypsin, add 3 mL solution of 0.1% soybean trypsin inhibitor (ATCC 30-2104). br />
- Centrifuge cell suspension at 125 x g for 5 to 10 minutes. Resuspend cell pellet in complete culture medium br />
- Add appropriate aliquots of the cell suspension to new culture vessels.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:4 is recommended
Medium Renewal: Every 2 to 3 days
Note: Lots manufactured prior to 05/20/2020 may have used a different cryopreservative, contact technical service if needed.
Quality control specifications
- Bacterial and fungal testing
- Not detected
- Mycoplasma contamination
- Not detected
- Virus testing
-
Hepatitis B virus (HBV): Not detectedCytomegalovirus (CMV): Not detectedHuman Immunodeficiency virus (HIV): Not detectedEpstein-Barr virus (EBV): Not detectedHuman papillomavirus (HPV): Not detected
- Functional tests
- Genotype testing for KI mutation: PCR bands at 813 bp and 528 bp corresponding to ECAD-EmGFP LHA and RHA junctions; Sanger sequencing confirms junction sequences.
- STR profiling
-
Amelogenin: XCSF1PO: 10,12D13S317: 8,9D16S539: 11,12D5S818: 10,13D7S820: 10,11TH01: 8,9.3TPOX: 9,11vWA: 15,17
History
- Depositors
- ATCC
Legal disclaimers
- Intended use
- This product is intended for laboratory research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use.
- Warranty
-
The product is provided 'AS IS' and the viability of ATCC® products is warranted for 30 days from the date of shipment, provided that the customer has stored and handled the product according to the information included on the product information sheet, website, and Certificate of Analysis. For living cultures, ATCC lists the media formulation and reagents that have been found to be effective for the product. While other unspecified media and reagents may also produce satisfactory results, a change in the ATCC and/or depositor-recommended protocols may affect the recovery, growth, and/or function of the product. If an alternative medium formulation or reagent is used, the ATCC warranty for viability is no longer valid. Except as expressly set forth herein, no other warranties of any kind are provided, express or implied, including, but not limited to, any implied warranties of merchantability, fitness for a particular purpose, manufacture according to cGMP standards, typicality, safety, accuracy, and/or noninfringement.
- Disclaimers
-
This product is intended for laboratory research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. Any proposed commercial use is prohibited without a license from ATCC.
While ATCC uses reasonable efforts to include accurate and up-to-date information on this product sheet, ATCC makes no warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. ATCC does not warrant that such information has been confirmed to be accurate or complete and the customer bears the sole responsibility of confirming the accuracy and completeness of any such information.
This product is sent on the condition that the customer is responsible for and assumes all risk and responsibility in connection with the receipt, handling, storage, disposal, and use of the ATCC product including without limitation taking all appropriate safety and handling precautions to minimize health or environmental risk. As a condition of receiving the material, the customer agrees that any activity undertaken with the ATCC product and any progeny or modifications will be conducted in compliance with all applicable laws, regulations, and guidelines. This product is provided 'AS IS' with no representations or warranties whatsoever except as expressly set forth herein and in no event shall ATCC, its parents, subsidiaries, directors, officers, agents, employees, assigns, successors, and affiliates be liable for indirect, special, incidental, or consequential damages of any kind in connection with or arising out of the customer's use of the product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, ATCC is not liable for damages arising from the misidentification or misrepresentation of such materials.
Please see the material transfer agreement (MTA) for further details regarding the use of this product. The MTA is available at www.atcc.org.
Permits & Restrictions
Material Transfer Agreement Addendum for Screening Applications
For-profit organizations
For every order of this item, you must provide a signed Material Transfer Agreement Addendum for Screening Applications. We cannot ship this item until we receive this addendum. The person signing the addendum as the principal investigator must match the end user as listed on the applicable sales order for the item.
Email the signed addendum to [email protected] with a reference to both your account and sales order numbers. Once received, your addendum will be reviewed, and this item will be released for shipment if all requirements are met. Additional fees may apply if this product is being used for a screening use (ATCC ACS-2103F), and these fees will be applied after your order is confirmed. If you need assistance with your order, please contact our Customer Care team or your applicable distributor.
This material is subject to the following restrictions in addition to those outlined in the ATCC Material Transfer Agreement:
For information on obtaining additional rights, please contact:
ATCC Licensing
Email: [email protected]
This material is subject to the following restrictions in addition to those outlined in the ATCC Material Transfer Agreement:
For information on obtaining additional rights, please contact:
ATCC Licensing
Email: [email protected]
Frequently Asked Questions
References
Curated Citations
Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7(2): 131-142, 2006. PubMed: 16493418
Richardson F, et al. The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy. Anticancer Res 32(2): 537-552, 2012. PubMed: 22287743
Soule H, McGrath CM. Immortal human mammary epithelial cell lines. US Patent 5,026,637 dated Jun 25 1991
Pauley RJ, et al. Immortal human mammary epithelial cell sublines. US Patent 5,206,165 dated Apr 27 1993
Soule HD, McGrath CM. A simplified method for passage and long-term growth of human mammary epithelial cells. In Vitro Cell. Dev. Biol. 22: 6-12, 1986. PubMed: 2418007
Powered by Bioz
For product-related inquiries and issues, contact Technical Service:
Hours of Operation
Monday - Friday
9:00am - 5:00pm
US Eastern Time
US Eastern Time
